Oxygen Atom Of The Saccharide Radical Is Bonded To A Cyclohexyl Radical (e.g., Kasugamycin, Etc.) Patents (Class 435/79)
  • Patent number: 5391481
    Abstract: The present invention provides an antibody which specifically forms a complex with and inhibits collagen binding to VLA-1 and methods of using same.
    Type: Grant
    Filed: August 31, 1990
    Date of Patent: February 21, 1995
    Assignee: The Trustees of Columbia University
    Inventors: Leonard Chess, Ilan Bank
  • Patent number: 5391272
    Abstract: An electro-immunosensor which can be used to determine the presence of a wide range of analytes in solution is described. Also described are methods of determining subnanogram levels of analytes in a one-step procedure. This novel immunosensor comprises an analyte binding agent bound to an electrode and a analyte/enzyme conjugate bound to the analyte binding agent as part of a catalytic electrical circuit. Displacement of the conjugate by analyte causes a proportional decrease in current. The immunosensor may also be adapted to detect two analytes in a single step by using different enzymes conjugated to the analyte binding agents.
    Type: Grant
    Filed: March 8, 1994
    Date of Patent: February 21, 1995
    Assignee: Andcare, Inc.
    Inventors: John P. O'Daly, Robert W. Henkens, Junguo Zhao, Honghua Zhang
  • Patent number: 5389522
    Abstract: At the initial diagnosis of sepsis (6-24 h before the development of ARDS), serum manganese superoxide dismutase (MnSOD) levels and catalase activities are increased in septic patients who subsequently developed ARDS compared to septic patients who did not develop ARDS. Increases in MnSOD and catalase may be used to predict the occurrence of ARDS in septic patients with the same sensitivity, specificity and efficiency as parallel assessments of serum lactate dehydrogenase (LDH) and Factor VIII levels. Evaluation of serum MnSOD and catalase as well as these other accessible markers facilitates identification of subsets of patients and allows prospective treatment of septic patients who are destined to develop ARDS.
    Type: Grant
    Filed: March 19, 1993
    Date of Patent: February 14, 1995
    Inventors: John E. Repine, Jonathan A. Leff
  • Patent number: 5389518
    Abstract: The present invention provides monoclonal antibodies directed against specific domains of fibronectin and vitronectin. These monoclonals may be used in the production of the biomaterial and devices for use in in vitro cell culture. The present invention also provides an efficient method for extracting vitronectin from bovine serum or plasma using monoclonal antibodies and methods for analyzing biological samples for the presence of adhesive glycoproteins or fragments thereof.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: February 14, 1995
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: John G. Steele, Patricia A. Underwood
  • Patent number: 5382516
    Abstract: The invention provides a method for supplying an enzyme substrate to a membrane-based, enzyme-linked reaction, comprising providing an open pore, high liquid retention capacity material impregnated with a predetermined amount of a substrate for the enzyme; and contacting the material with a membrane containing the enzyme-linked reaction under conditions which permit diffusion of the enzyme substrate to sites on the membrane containing the enzyme linked reaction.
    Type: Grant
    Filed: September 15, 1992
    Date of Patent: January 17, 1995
    Assignee: Schleicher & Schuell, Inc.
    Inventors: Christopher N. Bush, Charlene A. Audette, Michael A. Harvey
  • Patent number: 5380647
    Abstract: A rapid, simple, sensitive and reliable method for detecting fecal carcinoembryonic antigens in stool, indicative of the presence of the colorectal cancer is described. The invention is based on the discovery that previous methods of removing coarse and gelatinous materials from a stool and liquid mixture resulted in removing a significant amount of total CEA and CEA-like substances. By not removing or destroying or altering molecules smaller than 500,000 MW, in the process of preparing the stool sample to be examined, a significant portion of CEA and CEA-like substances will remain in the filtered liquid for detection.
    Type: Grant
    Filed: April 26, 1993
    Date of Patent: January 10, 1995
    Assignee: Farrokh Saidi
    Inventor: Kamal Bahar
  • Patent number: 5378608
    Abstract: An enzyme immunoassay for an antigen using a solid phase, which employs (a) a biotinylated antibody in which a biotin derivative is bound to a thiol group of an Fab' fragment of an antibody, (b) an enzyme-labelled antibody, and (c) a solid phase immobilized with a substance capable of specifically reacting with the above biotin derivative selected from the group consisting of avidin, streptoavidin and a derivative thereof which is bound to the solid phase directly or via a linkage between another biotin derivative and a high molecular weight substance bound to the solid phase, or alternatively employs (a') a solid phase immobilized with a biotinylated antibody via a substance selected from the group consisting of avidin, streptoavidin and a derivative thereof wherein said substance is bound to the biotin moiety of said biotinylated antibody and is also bound to the solid phase directly or via a linkage between another biotin derivative and a high molecular weight substance bound to the solid phase, and (b') a
    Type: Grant
    Filed: June 22, 1990
    Date of Patent: January 3, 1995
    Assignee: Nippon Shoji Kabushiki Kaisha
    Inventors: Yoji Marui, Chozo Hayashi, Shigeki Ito, Mieko Fujio, Hiroki Tanaka, Toshihide Nagasaki, Yasuji Soda, Hitoshi Kaneta
  • Patent number: 5376531
    Abstract: The invention provides a method of screening for gastrointestinal cancer in a mammal comprising: (a) contacting a body fluid taken from the mammal with N3; (b) measuring the amount of antibody to N3 in the body fluid; and (c) determining if the amount of antibody measured in step (b) is higher than the amount of antibody to N3 normally present in the same type of body fluid taken from mammals of the same species that do not have cancer. The invention also provides kits for screening for gastrointestinal cancer in a mammal by measuring the mammal's level of antibodies to N3.
    Type: Grant
    Filed: September 3, 1992
    Date of Patent: December 27, 1994
    Assignee: Northwestern University
    Inventors: Byron E. Anderson, Lyman E. Davis
  • Patent number: 5374533
    Abstract: A method for determining chondrocalcin through an immunoassay using an enzyme(s)-labeled mammalian chondrocalcin or enzyme(s)-labeled anti-chondrocalcin antibody which is characterized by that mammalian body fluid is used as a specimen and immunoreaction in a solution is utilized to determine the chondrocalcin of the mammalian, reagents and a kit therefor.This determination can be utilized for diagnosis or the like for cartilage-relating diseases in mammals.
    Type: Grant
    Filed: April 23, 1993
    Date of Patent: December 20, 1994
    Assignee: Tetjin Limited
    Inventors: Kimihiko Matsuzawa, Kazuhiko Itou, Hitomi Honda, Ryoichi Hasegwwa, Naomi Okamoto, Kenji Hosoda, Masayuki Shinmei, Shigeo Matsuyama
  • Patent number: 5374532
    Abstract: A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E.
    Type: Grant
    Filed: August 31, 1992
    Date of Patent: December 20, 1994
    Assignee: The Biomembrane Institute
    Inventors: Ann Stapleton, Edward Nudelman, Sen-itiroh Hakomori, Walter E. Stamm
  • Patent number: 5374519
    Abstract: Protein compositions containing the p18 and p25 proteins of the lymphadenopathy virus are used for detecting antibodies in blood serum as indicative of infection by such virus. The proteins can be used in various conventional ways to perform immunoassays for the detection of the antibodies.
    Type: Grant
    Filed: September 28, 1992
    Date of Patent: December 20, 1994
    Assignee: Institut Pasteur
    Inventors: Luc Montagnier, Jean-Claude Chermann, Francoise Barre-Sinoussi, Francoise Vezinet-Brun, Christine Rouzioux, Willy Rozenbaum, Charles Dauguet, Jacqueline Gruest, Marie-Theresa Nugeyre, Francoise Rey, Claudine Axler-Blin, Solange Chamaret
  • Patent number: 5374529
    Abstract: Methods of and compositions for early diagnosis, monitoring and treatment of osteoarthritis using monoclonal antibodies which specifically recognize antigenic determinants on atypical chondroitin sulfate/dermatan sulfate glycosaminoglycan chains in body tissues and fluids, which determinants are markers of osteoarthritis.
    Type: Grant
    Filed: November 1, 1991
    Date of Patent: December 20, 1994
    Inventors: Bruce Caterson, Timothy E. Hardingham
  • Patent number: 5373092
    Abstract: This invention relates to the production of derivatives of hydroxymethoxy mandelic acid (HMMA) and homvanillic acid (HVA), to their use in raising antibodies, and in the production of labelled compounds, and to the use of such materials in immunoassays for HMMA and HVA.
    Type: Grant
    Filed: September 15, 1993
    Date of Patent: December 13, 1994
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Gerard Gallacher, Geoffrey W. Mellor, Yee-Ping Ho
  • Patent number: 5372931
    Abstract: Aqueous compositions, test kits, test devices and methods can be used to detect hydrogen peroxide or peroxidase by generating a colorimetric or chemiluminescent signal in the presence of the analyte. Signal generation is enhanced by the presence of certain substituted 4-hydroxy- or 4-alkoxy-substituted phenyl or naphthyl electron transfer agents.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: December 13, 1994
    Assignee: Eastman Kodak Company
    Inventors: Alan E. Friedman, Thomas R. Kissel
  • Patent number: 5372932
    Abstract: A dry analytical element can be used to sensitively and rapidly detect a wide variety of specific binding ligands in either a competitive binding or sandwich assay format. The assays are carried out using a peroxidase-labeled immunoreactant. The peroxidase label is stabilized with a 4-hydroxy or 4-alkoxyarylacetamide which is located in one or more zones of the element. Not only is the label stabilized with the stabilizer, but the assay is more sensitive.
    Type: Grant
    Filed: December 22, 1992
    Date of Patent: December 13, 1994
    Assignee: Eastman Kodak Company
    Inventors: Alan E. Friedman, Linda A. Mauck, Thomas R. Kissel
  • Patent number: 5369002
    Abstract: An easy method for detecting injured cell nuclear DNA is provided which does not suffer from "pseudo-positive" staining. The method comprises the steps of subjecting a pathological tissue specimen to acid-hydrolysis to selectively hydrolyze any injured DNA thereby to form single-stranded DNA, then treating the specimen with an anti-single-stranded DNA antibody, and subjecting the specimen to morphological inspection to find the presence of the binding of the antibody to the single-stranded DNA. The binding may be discriminated by a labelling marker on the antibody. Alternatively, a labelled secondary antibody which binds to the anti-ssDNA antibody may be used.
    Type: Grant
    Filed: March 31, 1993
    Date of Patent: November 29, 1994
    Assignee: Maruzen Petrochemical Co., Ltd.
    Inventor: Masaru Fukuda
  • Patent number: 5369010
    Abstract: Novel cell lines, receptors and monoclonal antibodies prepared therefrom that are specific for the human HLA-B27 antigen are provided. The monoclonal antibodies are useful in diagnosis and therapy, particularly with respect to certain rheumatoid disorders.
    Type: Grant
    Filed: February 5, 1993
    Date of Patent: November 29, 1994
    Assignee: Genetic Systems Corporation
    Inventors: Karen A. Nelson, Douglas M. Strong
  • Patent number: 5369007
    Abstract: A microassay card includes an upper layer containing wells for receiving a liquid sample. A second layer of the card, beneath the first layer, includes a supporting surface bound to a reactive species. A third layer includes a superabsorbent support impregnated with an indicator. Typically, the indicator is a substrate for an enzyme, such as a reduced dye precursor and a source of hydrogen peroxide necessary for the action of the enzyme upon the substrate to cause a spectral change in the absorbent layer. By selecting the structure of the first and second layers, the card can be formatted for a displacement assay or a competitive assay. The microassay card of the present invention is particularly useful for drug testing.
    Type: Grant
    Filed: August 26, 1992
    Date of Patent: November 29, 1994
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: David A. Kidwell
  • Patent number: 5366866
    Abstract: A method for detecting the presence of cancer employs monoclonal antibody OXA or OXB, antibodies which bind to the antigen bound by monoclonal antibody OXA or OXB, or fragments of the foregoing which bind to the antigen bound by monoclonal antibody OXA or OXB. The method comprises contacting a sample of a biological fluid from a subject with the antibody under conditions permitting the antibody to form a reaction product, and then detecting the presence or absence of the reaction product. The method is particularly useful for monitoring the progression of treatment in a patient previously diagnosed as having ovarian cancer. The method is also useful for detecting and monitoring endometrial cancer.
    Type: Grant
    Filed: May 6, 1992
    Date of Patent: November 22, 1994
    Assignee: Duke University
    Inventors: Fengi J. Xu, Yinhua Yu, Robert C. Bast, Jr.
  • Patent number: 5366864
    Abstract: A buffered aqueous composition is useful simultaneously as a wash solution and a dye-providing composition in specific binding assays involving enzyme-labeled specific binding reagents. The wash composition includes a dye-providing composition, a buffer and an organic solvent having a certain molecular weight and water-solubility. Another useful composition includes a particulate substrate having avidin attached thereto, and a peroxidase reducing agent. Either composition can be provided in a diagnostic test kit, and can be used to detect a specific binding ligand in assays.
    Type: Grant
    Filed: September 30, 1992
    Date of Patent: November 22, 1994
    Assignee: Eastman Kodak Company
    Inventors: Gregory J. McClune, Karen L. Findling
  • Patent number: 5364591
    Abstract: There are described a device and method for doing confined reactions such as PCR amplification and detection, wherein solids (e.g., beads) used to obtain separation between bound and "free" label reagents, are transferred from region to region, specifically through a wash liquid so as to wash off the "free" label reagent from the solids. Separate chambers have dividers that are overcome by piercing or by liquification, to create passageways for the transfer of the solids. The passageways remain contained within the device.
    Type: Grant
    Filed: June 1, 1992
    Date of Patent: November 15, 1994
    Assignee: Eastman Kodak Company
    Inventors: Nancy F. Green, Thomas J. Cummins, Fred T. Oakes
  • Patent number: 5362627
    Abstract: Hydroxy coumarin ester enzyme substrates can be stored in a strong base at pH above 11 to stabilize the substrate against premature hydrolysis of the ester bond and to reduce the revel of contaminating hydroxy coumarin. When diluted in buffer at pH below 11 shortly before use in an enzyme assay, the substrate solution provides low background fluorescence.
    Type: Grant
    Filed: September 12, 1988
    Date of Patent: November 8, 1994
    Assignee: E. I. Du Pont de Nemours and Company
    Inventors: Richard A. Blumenthal, Hon-Peng P. Lau, Esther K. Yang
  • Patent number: 5358850
    Abstract: The present invention relates to a process of preparing a sandwich immunoassay of NAG, which comprises (1) reacting NAG with an immobilized anti-NAG monoclonal antibody and a labeled anti-NAG monoclonal antibody to form a complex of immobilized antibody-NAG-labeled antibody and (2) detecting the activity of said reacted and unreacted labeled anti-NAG antibody.This sandwich immunoassay is useful for diagnosis of renal disease, hepatitis, leukemia, and other such diseases. It also allows the direct and specific detection of NAG isozymes B and I in urine and blood.
    Type: Grant
    Filed: June 18, 1993
    Date of Patent: October 25, 1994
    Assignee: Shionogi Seiyaku Kabushiki Kaisha
    Inventors: Yoshito Numata, Yoko Kosugi, Kazunori Shibata
  • Patent number: 5358852
    Abstract: A specific binding immunoassay method for reducing the "hook" effect for the measurement of C-Reactive Protein has been discovered for both solution and dry analytical elements comprising contacting a liquid sample containing C-reactive protein in the presence of calcium ions with (a) a first antibody Ab1 specific for C-reactive protein, Ab1 being immobilized on a water-insoluble substrate and (b) a labeled, unbound second antibody Ab2 specific for C-reactive protein to obtain a water-insoluble complex of Ab1, ligand, and Ab2; (2) separating the water-insoluble complex from the liquid sample and unreacted Ab2; and (3) measuring either the amount of Ab2 associated with said water-insoluble complex or the amount of unreacted Ab2 as an indication of the amount of C-reactive protein in the sample.
    Type: Grant
    Filed: December 21, 1992
    Date of Patent: October 25, 1994
    Assignee: Eastman Kodak Company
    Inventor: Annie L. Wu
  • Patent number: 5356783
    Abstract: A sulfated glycoprotein with a molecular weight of approximately 45 kda inhibits the activation of tissue factor and thus inhibits the coagulation of blood. This glycoprotein can be used for treatment or prevention of intravascular clotting.
    Type: Grant
    Filed: January 25, 1993
    Date of Patent: October 18, 1994
    Assignee: W. Alton Jones Cell Science Center, Inc.
    Inventors: Vincenzo Buonassisi, Patricia C. Colburn
  • Patent number: 5356784
    Abstract: A method for determining the amount of analyte in a sample utilizes a series of test regions with systematically varied, preferably monotonically increasing, affinity for a specific binding partner for an analyte or for the analyte itself. By determining the portion of test regions which are capable of binding specific binding partner in competition with the analyte in the sample, or which bind the analyte, the amount of analyte may be estimated. Thus, titration of affinity replaces titration of concentration, allowing assays to, be performed without the need for serial dilution steps.
    Type: Grant
    Filed: March 30, 1993
    Date of Patent: October 18, 1994
    Assignee: Terrapin Technologies, Inc.
    Inventor: Lawrence M. Kauvar
  • Patent number: 5356782
    Abstract: The invention is an apparatus useful in carrying out an analytical assay. The apparatus has a positive and negative control, as well as a site for determining the presence, amount, or lack of an analyte in a sample.
    Type: Grant
    Filed: September 3, 1992
    Date of Patent: October 18, 1994
    Assignee: Boehringer Mannheim Corporation
    Inventors: David R. Moorman, David J. Ledden, David D. Webster, Brian A. Heald
  • Patent number: 5354655
    Abstract: There is disclosed a process and a device for detecting and measuring (1) the amount of enzyme present as a detecting system following a nucleic acid hybridization reaction or immunoreaction; (2) the level and activity of free enzyme in a biological sample; (3) the level of enzyme from contaminating microorganisms present in a sample; and (4) enzymes from pure culture isolates for microbial identification and antimicrobial susceptibility testing.
    Type: Grant
    Filed: March 29, 1988
    Date of Patent: October 11, 1994
    Assignee: BioControl Systems, Inc.
    Inventors: N. Robert Ward, Jr., Philip J. Lozier
  • Patent number: 5354659
    Abstract: A method for the detection of the presence of inflammation in a patient by measuring the amount of circulating intercellular adhesion molecule (cICAM-1) in a sample of one or more bodily fluids of the patient and then comparing the amount of cICAM-1 in the sample to standards normal for the bodily fluid or fluids assayed. The amount of cICAM-1 can be measured using anti-ICAM-1 antibodies. Higher than normal amounts of cICAM-1 indicate the presence of inflammation.
    Type: Grant
    Filed: October 21, 1992
    Date of Patent: October 11, 1994
    Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Robert Rothlein, Steven D. Marlin
  • Patent number: 5344760
    Abstract: Diagnostic/prognostic methods are provided for detecting and/or quantitating in the body fluids, preferably serum, of mammals carrying a malignant tumor burden, elevated levels of a portion of the epidermal growth factor receptor (EGFr) which comprises substantially the EGFr ectodomain having a molecular weight in the range of from about 90 kilodaltons (kd) to about 115 kd, preferably from about 95 kd to about 105 kd, and more preferably about 100 kd. Substantially pure compositions comprising said EGFr ectodoman protein and/or fragments thereof are disclosed as well as test kits for performing the disclosed assays.
    Type: Grant
    Filed: May 27, 1992
    Date of Patent: September 6, 1994
    Assignee: Ciba Corning Diagnostics Corp.
    Inventors: Jeanne P. Harvey, Victoria A. Crebbin, Roger P. Walker, Victor Liu, Susan L. Hammond, Patricia A. McDonald
  • Patent number: 5338660
    Abstract: A stable antigen useful in the detection of Fasciola hepatica (or liver fluke) infections is disclosed. The antigen may be found in feces, bile, and intestinal contents. Monoclonal antibodies useful in detecting the antigen are disclosed. The method of this invention facilitates the detection of current Fasciola hepatica infections.
    Type: Grant
    Filed: July 12, 1991
    Date of Patent: August 16, 1994
    Assignee: Board of Supervisors of Louisiana State University and Agricutural and Mechanical College
    Inventors: Mohamed M. El Bahy, John B. Malone, Jr., William J. Todd, Kenneth L. Schnorr
  • Patent number: 5334503
    Abstract: An extraction composition is described which is buffered to a pH from about 8 to about 11 and which contains from about 1 to about 10 weight percent of a water-soluble cationic surfactant which is a quaternary ammonium salt or a mixture thereof and from about 1 to about 10 weight percent of an anionic surfactant which has a sulfate anion having from 6 to 14 carbon atoms and an alkali metal or ammonium cation. The extraction composition is used to extract antigens from Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis or Prevotella intermedia. Extracted antigens are determined using immunological methods. The extraction composition can be supplied as part of a diagnostic test kit.
    Type: Grant
    Filed: October 8, 1991
    Date of Patent: August 2, 1994
    Assignee: Eastman Kodak Company
    Inventors: Brian A. Snyder, Paul B. Contestable, Catherine T. Abrams, Elizabeth A. Grogan
  • Patent number: 5334528
    Abstract: Methods are described for making specific monoclonal antibodies useful for detection of cyclodienes in foods and environmental samples. Monoclonal antibodies specifically reactive with cyclodienes can detect accumulated pesticides in food, tissue or environmental samples. Extraction and preparation of organic samples for immunoassay in a polar-nonpolar reaction medium permits detection of halogenated organic ring structures at concentrations in samples.
    Type: Grant
    Filed: October 30, 1989
    Date of Patent: August 2, 1994
    Assignee: The Regents of the University of California
    Inventors: Larry H. Stanker, Martin Vanderlaan, Bruce E. Watkins
  • Patent number: 5330897
    Abstract: The present invention concerns lectins isolated from the genus Tritrichomonas which bind specifically to sialic acid. The invention further pertains to uses of such lectins, and to processes for their preparation. The invention is further drawn to neuraminidase, particularly from T. mobilensis.
    Type: Grant
    Filed: May 19, 1992
    Date of Patent: July 19, 1994
    Assignee: South Alabama Medical Science Foundation
    Inventors: Frank F. Pindak, David J. Wells, Pavol Demes
  • Patent number: 5328829
    Abstract: The present invention comprises a method for the determination of periodontal disease active sites within the human oral cavity by a measurement of the level of interleukin 1 beta (IL-1b) in oral tissues and gingival crevicular fluid at a particular site.
    Type: Grant
    Filed: July 5, 1990
    Date of Patent: July 12, 1994
    Assignee: Forsyth Dental Infirmary for Children
    Inventor: Philip Stashenko
  • Patent number: 5328828
    Abstract: The instant invention is directed toward an immunoassay which can determine the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine by employing at least two conjugates, each comprised of a functionally similar label bound to an amphetamine analog and a methamphetamine analog respectively and an antibody to amphetamine and an antibody to methamphetamine wherein at least one of the antibodies is a monoclonal antibody.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: July 12, 1994
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Mae W. Hu, Cheng-I Lin, Chen-jung Hsu, James V. Freeman, Marcel Pirio, Edwin F. Ullman
  • Patent number: 5324667
    Abstract: The present invention relates to a method for detecting fetal Down syndrome (Trisomy 21), trisomy 13, trisomy 18 and other chromosomal anomalies during prenatal screening by analyzing blood samples from a pregnant woman. More particularly the present invention relates to a method for improving detection efficiency in screening for the anomalies by measuring the amount of the free beta human chorionic gonadotropin (HCG) and nicked or fragmented or aberrant forms of free beta (HCG), all of which are referenced throughout this application as free beta (HCG) in blood samples from pregnant women.
    Type: Grant
    Filed: August 7, 1992
    Date of Patent: June 28, 1994
    Inventor: James N. Macri
  • Patent number: 5324668
    Abstract: A method and apparatus for determining if a pregnant woman is at significant risk of carrying a fetus with Down syndrome, The method comprises measuring the pregnant woman's maternal blood levels of the free beta subunit of human chorionic gonadotropin. The level of free beta subunit of human chorionic gonadotropin individually or with other markers may be compared to reference data. A computerized apparatus for making the determination preferably using a probability density function generated from a set of reference data by a linear discriminant analysis procedure is disclosed.
    Type: Grant
    Filed: February 3, 1993
    Date of Patent: June 28, 1994
    Inventor: James N. Macri
  • Patent number: 5322772
    Abstract: A competitive protein binding assay for rapamycin and biologically-active metabolites, derivatives and analogues thereof in blood and other biological fluids is disclosed, wherein the binding reagent is a specific rapamycin binding protein either substantially purified from the soluble cytoplasm of target cells of rapamycin action, particularly normal or transformed lymphocytes, freshly collected or in established cell lines, or synthesized by recombinant DNA techniques. Solution phase and solid state assay systems are disclosed.
    Type: Grant
    Filed: April 9, 1991
    Date of Patent: June 21, 1994
    Assignee: Children's Research Institute
    Inventor: Steven J. Soldin
  • Patent number: 5320941
    Abstract: This invention provides a DNA sequence comprising an activated oncogene, said oncogene encoding a polypeptide capable of transforming NIH3T3 cells and of inducing a tumor when injected into nude mice, said DNA sequence having a nucleotide sequence substantially as shown in FIGS. 3A and 3B.The invention also concerns a polypeptide molecule encoded by an activated oncogene, said molecule having the properties of transforming NIH3T3 cells and of inducing a tumor when injected into nude mice and further said polypeptide having an amino acid sequence substantially as shown in FIGS. 3A and 3B.Finally, this invention provides a method for treating a tumor induced by an activated mas oncogene.
    Type: Grant
    Filed: June 6, 1986
    Date of Patent: June 14, 1994
    Inventors: Dallan Young, Michael H. Wigler, Ottavio Fasano
  • Patent number: 5321142
    Abstract: The invention relates to compounds from biopolymers and effector substances which are linked with the aid of derivatives of optically active amino acids in which the amino group has been converted into a maleimido group and the carboxyl group into an active ester group.
    Type: Grant
    Filed: July 6, 1990
    Date of Patent: June 14, 1994
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Heinz-Jurgen Friesen, Peter Hermentin
  • Patent number: 5316912
    Abstract: A method for detecting a glycoprotein using a solid support is disclosed where the glycoprotein is oxidized by periodate, polyacrylic polyhydrazide which is a copolymer having repeating units possessing a hydrazide group and repeating units possessing hydroxyl groups is coupled to the oxidized glycoprotein and a glycoenzyme or radioactive compound containing aldehyde groups or activated ketone groups is coupled to the polyacrylic polyhydrazide which allows for detection of the glycoprotein. The glycoprotein may be directly attached to the solid support or may be bound to an antigen which is immobilized on the solid support.
    Type: Grant
    Filed: December 13, 1989
    Date of Patent: May 31, 1994
    Inventors: Urs Heimgartner, Branko Kozulic, Klaus Mosbach
  • Patent number: 5316911
    Abstract: In a method of determining the presence of an endotoxin or endotoxin-like material in a sample, a) a sample is incubated with a component of horseshoe crab amoebocytes lysate or haemolymph or a synthetic analogue thereof, b) the incubated mixture of the sample and the component or analogue resulting from step a) is reacted with an antibody raised against the component or analogue or against a reaction product of the incubation of step a), and c) the presence of endotoxin or endotoxin-like material in the sample is determined by detecting any bound antibody in the reaction mixture of step b). In the method either the component or analogue or the antibody or the endotoxin or endotoxin-like material is coupled to a solid support.
    Type: Grant
    Filed: January 6, 1989
    Date of Patent: May 31, 1994
    Inventors: Leif Baek, Claus Koch
  • Patent number: 5316754
    Abstract: The present invention relates to a method and associated agents for measuring the presence and amount of advanced glycosylation endproducts in cells and fluids. The methods take advantage of the existence of receptors and receptor complexes for AGEs and include receptor-containing ligands comprising whole mesangial and other cells, mesangial cellular fragments and protein extracts therefrom. Competitive assays, sandwich assays and assays involving AGE antisera are disclosed. Numerous diagnostic applications are defined and test kits are also contemplated.
    Type: Grant
    Filed: January 28, 1993
    Date of Patent: May 31, 1994
    Assignee: The Rockefeller University
    Inventors: Helen Vlassara, Anthony Cerami
  • Patent number: 5317095
    Abstract: An .alpha.-D-hlycosyl kasugamycin having the formula (III): ##STR1## wherein n is an integer of not less than 1. According to the present invention, the novel substance which is highly safe and easily hydrolyzed with .alpha.-glucosidase to exhibit physiological activities inherent to kasugamycin is obtained.
    Type: Grant
    Filed: March 3, 1993
    Date of Patent: May 31, 1994
    Assignee: Hayashibara Biochemical Laboratories, Inc.
    Inventors: Yukio Suzuki, Koutarou Muroyama, Kei Suzuki
  • Patent number: 5316953
    Abstract: A screening method for fetal Down syndrome using free beta (HCG) as a marker. The maternal blood level of free beta (HCG) is measured and compared to reference data, at a similar gestational age, of the level of free beta (HCG) in pregnant women carrying a fetus with Down syndrome and pregnant women carrying an unaffected fetus. The method may advantageously be utilized during the first and second trimesters of pregnancy. Fragments of free beta and "nicked" free beta may also be utilized as markers.
    Type: Grant
    Filed: April 14, 1992
    Date of Patent: May 31, 1994
    Inventor: James N. Macri
  • Patent number: 5312729
    Abstract: The present invention relates to assay techniques for detection of ligands in solution and to means for putting such techniques into effect. In particular it relates to an improved assay technique which provides a liquid calibrator for use in standard assays in circumstances where the ligand itself is rare, expensive, or difficult to prepare in a sufficiently pure or quantifiable form.
    Type: Grant
    Filed: March 6, 1990
    Date of Patent: May 17, 1994
    Assignee: Ares-Serono Research & Development Limited Partnership
    Inventors: Gerald J. Allen, Madlyn D. Denyer, Grenville A. Robinson
  • Patent number: 5310655
    Abstract: In the case of a process for the detection of the functionability of the kidney tubules, one specifically determines the content of THP in the urine as measure of the function of the kidney tubules. One uses this process for the control of the transplant rejection after a kidney transplantation, for the detection of blood supply disturbances of the kidney and of kidney damages produced by prior oxygen deficiency supply. Processes for determining kidney function by measuring Tamm-Horsfall protein (THP) using a specific monoclonal antibody are disclosed.
    Type: Grant
    Filed: March 22, 1991
    Date of Patent: May 10, 1994
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Lothar Zimmerhackl, Rolf Kinne, Thomas Fabricius, Fricke Pietruschka, Mathias Brandis
  • Patent number: 5310656
    Abstract: A competitive immunoassay for vitamin B.sub.12 using labeled monoclonal antibodies to the vitamin B.sub.12 binding site on intrinsic factor and labeled intrinsic factor.
    Type: Grant
    Filed: June 12, 1992
    Date of Patent: May 10, 1994
    Assignee: Tritech Partners
    Inventors: Mohammad T. Pourfarzaneh, George W. Katsilometes
  • Patent number: 5308775
    Abstract: The novel analytical devices and methods of the present invention involve dual pathway devices which provide for the confirmation of sandwich or competitive assay results. In a self-confirming sandwich assay, the labeled analyte complex becomes immobilized within a first pathway at an assay capture site to indicate the presence or amount of an analyte in the test sample. In a second pathway, a confirmatory reagent blocks the binding of the analyte or labeled analyte complex to a confirming assay site, thereby confirming that the presence of label in the assay capture site indicates a positive test sample. In a self-confirming competitive assay, a confirmed positive result is one in which the device displays a decrease in signal or no signal at the assay capture site, and the confirming assay site displays a detectable signal.
    Type: Grant
    Filed: September 15, 1992
    Date of Patent: May 3, 1994
    Assignee: Abbott Laboratories
    Inventors: James J. Donovan, Stephen W. Worobec